FindTrial
Sign In

Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia

Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01505699
Enrollment
186
Registered
2012-01-06
Start date
2012-01-06
Completion date
2012-02-06
Last updated
2017-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Keywords

adult acute lymphoblastic leukemia in remission, B-cell adult acute lymphoblastic leukemia

Brief summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.

Detailed description

OBJECTIVES: * To identify microRNAs that behave as oncogenes or as tumor suppressor genes in B-lineage acute lymphoblastic leukemia (ALL) in vitro and in vivo. * To examine if single microRNA or signatures of microRNA correspond to different clinical outcomes in cytogenetically distinct B-ALL groups. OUTLINE: RNA from archived samples are analyzed for microRNA expression profile in vitro and in vivo.

Interventions

GENETICRNA analysis
GENETICcytogenetic analysis
GENETICmicroarray analysis
OTHERlaboratory biomarker analysis

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Eastern Cooperative Oncology Group
Lead SponsorNETWORK

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Samples from patients enrolled on ECOG-2993 * Samples from patients with recurrent cytogenetic abnormalities other than BCR-ABL, including MLL/AF4, E2A/PBX1, and TEL/AML1 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

MeasureTime frame
Comprehensive view of microRNA expression by cytogenetic subgroup1 year
MicroRNA expression in relation to clinical outcome1 year
Differential microRNA expression between normal B-cells and progenitors compared to B-ALL1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026